British drugmaker GSK on Friday sold 240 million shares in its consumer healthcare business Haleon at 335 pence per share, raising about 804 million pounds ($1 billion), the company said.
Tag Archive for: GSK
The company’s CFO said Pfizer has long been clear about its intention to sell off the stake, suggesting that the reason the potential of the selloff has gained traction is because the selling window opens around the time that Haleon’s results are announced.
Brussels on Wednesday published a long-awaited draft of its proposed overhaul of laws governing the European Union’s pharmaceuticals industry, setting up a tussle with drugmakers which warn they will invest and innovate elsewhere.
GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results thanks to strong sales of its vaccines as well as HIV and respiratory medicines.
British drugmaker GSK on Wednesday warned that the overhaul of laws governing the EU’s pharmaceuticals industry risks forcing companies to invest and innovate elsewhere, which would hurt EU efforts to improve access to medicines.
Hundreds of GSK workers have voted to stage a series of walkouts at UK manufacturing sites in May over a dispute over pay, in what could be a first at the British drugmaker, labour union Unite said on Wednesday.
Tuesday, GSK signed an acquisition agreement with Bellus Health for $2 billion to gain access to the Canadian biotech’s chronic cough candidate camlipixant.
Ghana has become the first country in the world to approve a new malaria vaccine from Oxford University, a potential step forward in fighting a disease that kills hundreds of thousands of children each year.
Antimicrobial resistance (AMR) is a growing threat to global health and was associated with 4.95 million deaths in 2019 globally, more than HIV and malaria combined, as of the WHO’s last readout. Vaccines can be effective tools in combating AMR and have been highlighted by WHO.
In two papers published Wednesday in the New England Journal of Medicine, Pfizer touted positive Phase III data for its respiratory syncytial virus (RSV) vaccine candidate, showing high levels of protection for older adults and infants.
